Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aeris Therapeutics Inc.

This article was originally published in Start Up

Executive Summary

Aeris Therapeutics offers a minimally invasive, biological alternative to lung volume reduction surgery for emphysema.

You may also be interested in...

Lung Cancer: An Up and Coming Device Market

Lung cancer is the number one cause of deaths from cancer, in large part because it generally isn't detected until very late stages. At that point, survival rates are low and the only option is radical lung surgery. But now imaging technologies can detect smaller cancers, sooner, and in the wake of the publication of the Early Lung Cancer Action Project, the medical device industry is preparing for a paradigm shift. Start-ups are now developing technologies to remove the barriers in diagnosis and access that hinder therapeutic intervention.

Devices Fill The Lung Space

Interventional pulmonology may be a specialty device market, but its diseases, including COPD, asthma and lung cancer, are enormous and growing.

NETT Sends Mostly Positive Message for Controversial Lung Procedure

The mystery is over; the results of the National Emphysema Treatment Trial Research Group (NETT) have been unveiled, and it's by and large good news for device companies in interventional pulmonology. Although the outcomes are mixed and underscore the need for proper patient selection, clinicians are now hoping that clinical benefits demonstrated by NETT, a 1218-patient, five-year randomized prospective clinical trial comparing lung volume reduction surgery to medical management, will support reimbursement for the surgery.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts